Federated Hermes Inc. Sells 1,685 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Federated Hermes Inc. decreased its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 1.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 108,577 shares of the company’s stock after selling 1,685 shares during the period. Federated Hermes Inc. owned 0.11% of Neurocrine Biosciences worth $14,306,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of NBIX. Sunbelt Securities Inc. lifted its stake in Neurocrine Biosciences by 34.3% in the 3rd quarter. Sunbelt Securities Inc. now owns 325 shares of the company’s stock valued at $37,000 after purchasing an additional 83 shares during the last quarter. Red Spruce Capital LLC lifted its stake in Neurocrine Biosciences by 0.6% in the 4th quarter. Red Spruce Capital LLC now owns 16,026 shares of the company’s stock valued at $2,112,000 after purchasing an additional 101 shares during the last quarter. Metis Global Partners LLC lifted its stake in Neurocrine Biosciences by 4.7% in the 3rd quarter. Metis Global Partners LLC now owns 2,361 shares of the company’s stock valued at $266,000 after purchasing an additional 106 shares during the last quarter. Lmcg Investments LLC lifted its stake in Neurocrine Biosciences by 2.1% in the 3rd quarter. Lmcg Investments LLC now owns 9,427 shares of the company’s stock valued at $1,061,000 after purchasing an additional 193 shares during the last quarter. Finally, State of Michigan Retirement System lifted its stake in Neurocrine Biosciences by 0.9% in the 4th quarter. State of Michigan Retirement System now owns 23,581 shares of the company’s stock valued at $3,107,000 after purchasing an additional 200 shares during the last quarter. Institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Trading Up 1.3 %

Shares of NBIX opened at $133.66 on Tuesday. The stock has a market capitalization of $13.30 billion, a P/E ratio of 55.23 and a beta of 0.25. The firm’s fifty day simple moving average is $136.21 and its two-hundred day simple moving average is $127.35. Neurocrine Biosciences, Inc. has a 12 month low of $89.04 and a 12 month high of $148.37.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Wednesday, February 7th. The company reported $1.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.13 by $0.31. The company had revenue of $515.20 million for the quarter, compared to analysts’ expectations of $518.52 million. Neurocrine Biosciences had a net margin of 13.23% and a return on equity of 12.85%. The business’s revenue was up 25.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.88 EPS. As a group, research analysts predict that Neurocrine Biosciences, Inc. will post 4.84 EPS for the current fiscal year.

Insider Transactions at Neurocrine Biosciences

In other news, insider Eiry Roberts sold 1,457 shares of the stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $140.79, for a total transaction of $205,131.03. Following the transaction, the insider now owns 20,832 shares of the company’s stock, valued at approximately $2,932,937.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Neurocrine Biosciences news, Director Richard F. Pops sold 15,000 shares of the stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $132.47, for a total value of $1,987,050.00. Following the completion of the sale, the director now owns 29,512 shares in the company, valued at approximately $3,909,454.64. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Eiry Roberts sold 1,457 shares of the stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $140.79, for a total transaction of $205,131.03. Following the completion of the sale, the insider now owns 20,832 shares of the company’s stock, valued at approximately $2,932,937.28. The disclosure for this sale can be found here. Insiders have sold 186,994 shares of company stock valued at $25,806,409 in the last 90 days. 4.60% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

NBIX has been the subject of several recent analyst reports. StockNews.com upgraded shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 8th. Barclays raised their price objective on shares of Neurocrine Biosciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 23rd. Mizuho raised their price objective on shares of Neurocrine Biosciences from $116.00 to $140.00 and gave the stock a “neutral” rating in a research report on Thursday, February 8th. Wells Fargo & Company raised their price objective on shares of Neurocrine Biosciences from $127.00 to $140.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 8th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $155.00 price objective on shares of Neurocrine Biosciences in a research report on Wednesday, April 10th. Six equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $139.67.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.